EQRX Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Bronstein, Gewirtz & Grossman, LLC

Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

2 years ago - By: Kahn Swick & Foti, LLC

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

2 years ago - By: Robbins LLP

EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders

2 years ago - By: Benzinga

EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce

2 years ago - By: Benzinga

Earnings Outlook For EQRx

2 years ago - By: Brodsky & Smith LLC - Mentions: CPRI AVID TPR RVMD

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)

2 years ago - By: Kahn Swick & Foti, LLC

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

2 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines

2 years ago - By: Halper Sadeh LLC

EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders

2 years ago - By: Seeking Alpha - Mentions: RVMD

Revolution Medicines will buy EQRx in an all-stock transaction (NASDAQ:RVMD)

2 years ago - By: Revolution Medicines, Inc.; EQRx, Inc. - Mentions: RVMD

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

2 years ago - By: Seeking Alpha

EQRx GAAP EPS of -$0.17 misses by $0.03 (NASDAQ:EQRX)

2 years ago - By: EQRx, Inc.

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

3 years ago - By: EQRx, Inc.

EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

3 years ago - By: Robbins LLP

EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders

3 years ago - By: Seeking Alpha

EQRX stock lower as CFO departs (NASDAQ:EQRX)

3 years ago - By: Seeking Alpha

EQRx GAAP EPS of -$0.05 beats by $0.14 (NASDAQ:EQRX)

3 years ago - By: EQRx, Inc.

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

3 years ago - By: EQRx, Inc.

EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

3 years ago - By: EQRx, Inc.

EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer

3 years ago - By: EQRx, Inc.

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

3 years ago - By: Seeking Alpha - Mentions: GS

EQRX INC (EQRX) Stock News

EQRX Latest News, Press Relases and Analysis

Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders

EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce

Earnings Outlook For EQRx

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)

EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX

Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines

EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders

Revolution Medicines will buy EQRx in an all-stock transaction (NASDAQ:RVMD)

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

EQRx GAAP EPS of -$0.17 misses by $0.03 (NASDAQ:EQRX)

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders

EQRX stock lower as CFO departs (NASDAQ:EQRX)

EQRx GAAP EPS of -$0.05 beats by $0.14 (NASDAQ:EQRX)

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

EQRX stock extends post-earnings slump as Goldman Sachs, Jefferies downgrade (NASDAQ:EQRX)